Company Overview - 博锐生物 has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and JPMorgan serving as joint sponsors [1] - The company is a leading integrated biopharmaceutical firm in China, focusing on comprehensive immunotherapy solutions for autoimmune and inflammatory diseases, as well as tumor immunology [1] - 博锐生物 ranks first among Chinese pharmaceutical companies in revenue from biologics for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [1] - The company has eight commercialized products and is transitioning from a proven molecule development enterprise to an innovation-driven biopharmaceutical company, including the development of ADC candidates [1] Industry Insights - The autoimmune disease market is one of the fastest-growing pharmaceutical sectors globally, with blockbuster drugs like Dupilumab, Risankizumab, and Ustekinumab each generating over $10 billion in revenue in 2024 [1] - In China, the market size for autoimmune diseases is projected to grow from RMB 17.4 billion in 2020 to RMB 32.8 billion in 2024, and is expected to reach RMB 289.9 billion by 2035, with a compound annual growth rate (CAGR) of 21.9% [1] - The market share of biologics is rapidly expanding, increasing from RMB 4.2 billion in 2020 to RMB 17.1 billion in 2024, and is anticipated to reach RMB 212.6 billion by 2035 [1] Tumor Immunology Market - Tumor immunology is a cornerstone of modern cancer treatment, utilizing the immune system to identify and eliminate cancer cells, encompassing cell immunotherapy, cytokines, cancer vaccines, and antibody therapies [2] - The success of immune checkpoint inhibitors has transformed the landscape of tumor treatment [2] - The proportion of tumor immunotherapy drugs in the overall oncology drug market in China is expected to grow from 11.3% in 2024 to 47.5% by 2035 [2] - The market size for tumor immunotherapy drugs in China is projected to increase from RMB 14.8 billion in 2020 to RMB 29.3 billion in 2024, and further expand to RMB 495.4 billion by 2035 [2]

Core Viewpoint - The article discusses the biological inequality in cancer prevalence and mortality between men and women, highlighting the role of Y chromosome loss (LOY) as a significant factor in cancer progression and immune response in men [1][5][31]. Group 1: Research Findings - A study published in Nature by Chen Xingyu reveals how LOY affects both tumor cells and T cells, leading to poorer outcomes for male cancer patients [3][4][6]. - LOY is common in older men, with over 20% of men aged 60 and over showing detectable LOY in peripheral blood cells, previously considered a sign of aging but now linked to cancer progression [13][19]. - The study integrates data from over 4,000 male cancer samples and more than 1 million single-cell transcriptomic data, exploring the origins and clinical significance of LOY [19]. Group 2: Mechanisms of LOY - LOY not only occurs in tumor cells but also spreads to immune cells, particularly T cells, leading to a loss of anti-cancer capabilities [6][22]. - The presence of LOY in T cells correlates with immune suppression and functional exhaustion, indicating a systemic collapse in the immune response against cancer [21][28]. - The study suggests that LOY contributes to a "tumor-immune escape" mechanism, allowing cancer cells to proliferate unchecked [28]. Group 3: Clinical Implications - The findings propose a new LOY scoring system for survival prediction, which could aid in personalized treatment strategies for cancer patients [25][32]. - In cell therapies like CAR-T or TIL, the LOY status of reinfused cells should be a critical quality control metric to avoid reintroducing dysfunctional T cells [34]. - Future therapies targeting LOY-related immune deficiencies may represent a new direction in cancer immunotherapy [35]. Group 4: Gender Differences in Cancer - The study highlights that while the Y chromosome is male-specific, many key immune genes on the Y chromosome have homologous copies on the X chromosome in females, potentially explaining the stronger immune defenses in women [30][31]. - Understanding LOY provides insights into the molecular roots of gender differences in cancer susceptibility and outcomes [31][38].